Juvena Therapeutics utilizes an AI-driven platform to identify and engineer secreted proteins into biologic therapeutics that restore tissue homeostasis. The company addresses the dysregulation of protein signaling that leads to degenerative diseases, including myopathies and metabolic disorders.
Funding
$52.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+2Founders
Product
Problem
Degenerative diseases, including myopathies and metabolic disorders, arise from the dysregulation of protein signaling and intercellular communication, leading to a loss of tissue homeostasis. Current treatments often fail to address the underlying causes of this dysregulation. This results in a decline in healthy bodily functions and the progression of chronic conditions.
Solution
Juvena Therapeutics is developing tissue-restorative biologics by leveraging an AI-enabled platform to identify and engineer secreted proteins. The company's approach involves mining thousands of proteins secreted by human stem cells and screening their potential to restore tissue homeostasis. Through in silico mapping, in vitro human cell screening, in vivo pharmacology, and advanced protein engineering, Juvena creates novel biologic medicines. These therapeutics aim to repair protein signaling, promote tissue regeneration, and drive healthy communication between body systems, ultimately addressing the root causes of degenerative diseases.
Target Audience
The primary target audience includes patients suffering from myopathies such as Myotonic Dystrophy Type 1, as well as those with metabolic diseases like obesity and sarcopenia, and the clinicians who treat them.
Features
- AI-powered platform for rapid expansion of protein candidate library, hit generation, and target validation
- In silico mapping of secreted proteins to specific disease phenotypes
- In vitro human cell screening to assess protein functionality
- In vivo validation of protein bioactivity to optimize clinical impact and safety
- Advanced protein engineering to synthesize novel biologics
- Focus on disease-modifying biologics for myopathies and metabolic diseases
- First-in-class myotonic dystrophy program in partnership with the Myotonic Dystrophy Foundation